This CAR T-cell therapy has revolutionized the management of high-risk and relapsed or refractory disease.
Jordan D. Scott, PharmD
Advertisement
Articles by Jordan D. Scott, PharmD
An interdisciplinary discussion addresses the disparity in availability and use of these therapies across the continuum of care.
Advertisement
Latest Updated Articles
Operationalizing Bispecific Antibodies Across Academic and Community Oncology Centers in Hematologic MalignanciesPublished: June 25th 2024 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Regular Melatonin Supplementation May Hide Hidden Heart Complications
2
CDC Adolescents, Children, & Adult Immunization Schedule: 2025 Update
3
MFN, DTC, and the Policy Pressure Cooker: Reshaping the US Drug Market
4
PCV21-Unique Serotypes Most Prevalent in US Adults With Pneumococcal Disease
5
